The Leukemia & Lymphoma Society is urging the U.S. Department of Health and Human Services (HHS) to reverse detrimental changes to reimbursement rates for two lymphoma drugs. If the HHS does not act, the changes would severely limit the availability of the two therapies, which for thousands of non-Hodgkin lymphoma (NHL) patients represent their best or only resort for effective treatment....
Read More...
[Source: Society News]
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment